ABOS — Acumen Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Acumen jumps after equity raise to advance Alzheimer's drug development
Brief: Acumen Pharmaceuticals Announces $35.75 Million Private Placement To Advance Potential Best-In-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Brief: Acumen Pharmaceuticals To Showcase Advances In Alzheimer's Treatment At International Conference On Alzheimer’S And Parkinson’S Diseases 2026
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
Brief: Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
Biopharma firm Acumen's Q3 net loss narrows, beats estimates
Brief: Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -26.513 Million
U.S. RESEARCH ROUNDUP- Equifax, Johnson & Johnson, Morgan Stanley
Acumen Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acumen Pharmaceuticals Q2 net loss widens
Acumen Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Acumen Pharmaceuticals Presents Studies Showing Utility Of Ptau217 Assay In Screening For Phase 2 Alzheimer’S Disease Trial And Validates Sabirnetug Oligomer-Selectivity, At The Alzheimer’S Association International Conference (Aaic) 2025
Acumen Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Acumen Pharmaceuticals, Inc. Q1 Income From Operations USD -30.37 Million
Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a share - Earnings Preview
Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million
Brief: Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease
Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview